COVID-19 Lay Summary EMA Management of Clinical Trials

June 19, 2020
Previous Article
Critical Global Pandemic Safety Considerations: FDA Expectations for Responding to Employees in Pharmaceutical Manufacturing Infected with C
Critical Global Pandemic Safety Considerations: FDA Expectations for Responding to Employees in Pharmaceutical Manufacturing Infected with C

On June 19, 2020, FDA released a Guidance for Industry (GFI) entitled Good Manufacturing Practice Considera...

Next Article
Using risk assessment decision tree models to maintain safety and data validity in clinical trials during COVID-19
Using risk assessment decision tree models to maintain safety and data validity in clinical trials during COVID-19

During the COVID-19 pandemic, challenges to the conduct of clinical trials may arise, e.g. due to travel re...